Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Female or male aged ≥18 years~* History of type 2 diabetes mellitus for more than 12 months~* HbA1c≥7.0% and ≤11.0%~* Stable antidiabetic treatment during the last 12 weeks up to randomization~* eGFR 25-75 mL/minute/1.73m2, inclusive~* Micro or macroalbuminuria (UACR 30 - 3500 mg/g)~* Treatment with ACE inhibitor or an ARB for at least 3 months prior to screening~* Body mass index between 20 and 45 kg/m2~Exclusion Criteria:~* Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1:~  * Myocardial infarction~ * cardiac surgery or revascularization (CABG/PTCA)~ * unstable angina~ * unstable HF~ * New York Heart Association (NYHA) Class III-IV~ * transient ischemic attack (TIA) or significant cerebrovascular disease~ * unstable or previously undiagnosed arrhythmia~* Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency~* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) \> 3X ULN~* Total Bilirubin (TB) \>2 mg/dL (34.2 μmol/L)~* History of acute kidney injury requiring renal replacement therapy (dialysis or ultrafiltration) or any biopsy or imaging verifying intercurrent kidney disease other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis~* Ongoing treatment with a SGLT2 inhibitor, GLP-1 agonist or DPP4 inhibitors~* Any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient or patient suspected or with confirmed poor protocol or medication compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin 10mg (Type: EXPERIMENTAL): Tablets administered orally once daily for 24 weeks
- Dapagliflozin 10mg + Saxagliptin 2.5mg (Type: EXPERIMENTAL): Tablets administered orally once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Tablets administered orally once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).